Longeveron Inc., a clinical-stage biotechnology company, is dedicated to developing cell therapies for life-threatening and aging-related conditions. The company is headquartered in Miami, Florida.
| Revenue (TTM) | $1.19M |
| Gross Profit (TTM) | 828,000 |
| EBITDA | $-22.44M |
| Operating Margin | -2150.00% |
| Return on Equity | -203.60% |
| Return on Assets | -90.90% |
| Revenue/Share (TTM) | $0.49 |
| Book Value | $3.28 |
| Price-to-Book | 2.01 |
| Price-to-Sales (TTM) | 18.29 |
| EV/Revenue | 9.62 |
| EV/EBITDA | -49.61 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -9.20% |
| Shares Outstanding | $3.04M |
| Float | $2.57M |
| % Insiders | 15.14% |
| % Institutions | 20.55% |
Volatility is currently expanding
Longeveron to present at the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026; presentation 9/14/26 at 1:00pm ET
MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company's Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company's stockholders at the Company's annual meeting held on July 1, 2026 and the Company's Board of Directors on July 31, 2026.
Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company's executive leadership team in the role of Chief Financial Officer (“CFO”), principal financial officer and principal accounting officer. He succeeds Marie Washburn who stepped into the role following the retirement of the prior CFO.
Longeveron Inc. (LGVN) Q2 2026 Earnings Call Transcript
On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty Three new independent Directors join Longeveron's Board of Directors Company to host conference call and webcast today at 4:30 p.m. ET MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today reported financial results for the quarter ended June 30, 2026 and provided a business update.
MIAMI, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report 2026 second quarter financial results and provide a business update on Wednesday, August 12, 2026 after the U.S. financial markets close.
MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that Deborah D. Ascheim, M.D.
Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC) entitled “Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer's Disease Gray And White Matter Regions As Assessed Using Free Water MRI” presented at July 13th In Person Poster Presentation Session Results support a clinically relevant and long-lasting anti-inflammatory mechanism of action of laromestrocel in gray and white matter of the brain, indicate potential blood biomarker correlates with clinical outcomes, and support continued clinical development of laromestrocel for Alzheimer's disease Longeveron has received U.S. FDA RMAT designation for its Alzheimer's disease program and has aligned on a Phase 3 study design MIAMI, July 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that additional analysis of data from the Phase 2a clinical trial evaluating its stem cell therapy laromestrocel in mild Alzheimer's disease (AD) is being presented in a Poster Presentation at the 2026 Alzheimer's Association International Conference® (AAIC®), being held July 12-15, 2026 in London, United Kingdom and online. Results presented in “Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer's Disease Gray And White Matter Regions As Assessed Using Free Water MRI” provide support for a clinically relevant and durable anti-inflammatory mechanism of action of laromestrocel in gray and white matter and indicate potential blood biomarker correlates.
Ms. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech sectors Corporate focus on delivering top-line results from the Phase 2b clinical trial evaluating its stem cell therapy in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 MIAMI, July 06, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Marie Washburn to the Company's executive leadership team in the role of Senior Vice President and Chief Financial Officer (“CFO”), principal financial officer and principal accounting officer, effective July 13, 2026. She succeeds Lisa Locklear who, as previously announced, is stepping down to pursue board opportunities and other professional and personal interests.
Longeveron Inc. (LGVN) Shareholder/Analyst Call Prepared Remarks Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LGVN and any ticker you trade — then tracks every position and per-strategy win rate.
